P-glycoprotein in autoimmune diseases

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Multidrug resistance-1 (MDR-1) is mediated by P-glycoprotein (P-gp), a transporter effluxing various drugs.
• P-gp's role in cancer therapy failure is known, but its significance in autoimmune disorders is understudied.
• Abnormally activated cells in autoimmune diseases may exhibit drug resistance.

Purpose of the Study:

• To investigate the presence and implications of the MDR-1 phenotype in autoimmune disorders.
• To explore the potential link between P-gp activity and treatment response in autoimmune conditions.
• To identify drug resistance mechanisms in autoimmunity for therapeutic optimization.

Main Methods:

• Review of existing literature on P-gp function and its association with autoimmune diseases.
• Analysis of studies reporting P-gp substrate extrusion in lymphocytes of patients with rheumatoid arthritis, immune thrombocytopenic purpura, and systemic lupus erythematosus.
• Correlation of P-gp activity levels with treatment outcomes in patients with autoimmune disorders.

Main Results:

• Increased P-gp substrate extrusion observed in lymphocytes of patients with rheumatoid arthritis, immune thrombocytopenic purpura, and systemic lupus erythematosus.
• Higher P-gp activity values correlated with poorer treatment response in these patients.
• Potential contribution of long-term medication use inducing P-gp function to observed resistance.

Conclusions:

• The MDR-1 phenotype, characterized by P-gp overfunction, is present in lymphocytes of patients with autoimmune disorders.
• P-gp activity may contribute to therapeutic failures in autoimmune conditions.
• Targeting P-gp with inhibitors could optimize current treatment strategies for autoimmune diseases.